GT Biopharma
GTBP
57 hedge funds and large institutions have $12.9M invested in GT Biopharma in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 28 reducing their positions, and 7 closing their positions.
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
16% more call options, than puts
Call options by funds: $156K | Put options by funds: $135K
8% more funds holding
Funds holding: 53 → 57 (+4)
0.11% less ownership
Funds ownership: 0.6% → 0.49% (-0.11%)
23% less capital invested
Capital invested by funds: $16.7M → $12.9M (-$3.83M)
82% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$151K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$105K |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$75.8K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$62.9K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$57.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$642K |
| 2 |
Two Sigma Investments
New York
|
-$549K |
| 3 |
Morgan Stanley
New York
|
-$517K |
| 4 |
Renaissance Technologies
New York
|
-$354K |
| 5 |
Two Sigma Advisers
New York
|
-$298K |
GTBP Hedge Fund Activity: Q1 2022 in Review
57 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2022, worth a combined $12.9M — down 23% from $16.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new GTBP positions and 7 closed out — a net gain of 4 holders — while 5 added to existing stakes and 28 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $151K. The largest seller was Vanguard Group, cutting an estimated $642K.
- 57 institutional investors held GT Biopharma (GTBP) as of Q1 2022, up from 53 in Q4 2021.
- Funds reported $12.9M of GT Biopharma stock for Q1 2022, down 23% quarter-over-quarter.
- 11 funds opened new GT Biopharma positions in Q1 2022 and 7 closed out, a net change of +4 holders.
- The largest GT Biopharma buyer in Q1 2022 was Fidelity Investments, an estimated $151K added.
- The largest GT Biopharma seller in Q1 2022 was Vanguard Group, an estimated $642K sold.
Based on aggregated 13F filings for Q1 2022.